NeoGenomics NEO Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $745.97M+2.6% | $727.33M+2.6% | $709.16M+2.9% | $689.19M+2.5% | $672.36M+1.8% | ||
| $424.06M+2.7% | $413.04M+3.0% | $400.96M+3.7% | $386.55M+3.2% | $374.48M+1.1% | ||
| $321.91M+2.4% | $314.29M+2.0% | $308.21M+1.8% | $302.64M+1.6% | $297.88M+2.7% | ||
| 43.2%-0.1pp | 43.2%-0.2pp | 43.5%-0.5pp | 43.9%-0.4pp | 44.3%+0.4pp | ||
| $36.43M-1.7% | $37.08M+3.4% | $35.87M+2.9% | $34.86M+3.4% | $33.72M+8.2% | ||
| $93.15M+1.2% | $92.01M+1.2% | $90.9M+1.6% | $89.51M+2.8% | $87.11M+2.9% | ||
| $270.87M-0.9% | $273.34M0.0% | $273.47M+1.1% | $270.57M+3.2% | $262.15M+0.9% | ||
| $428.21M-0.5% | $430.17M+0.3% | $429.08M+2.7% | $417.69M+7.9% | $387.24M+1.3% | ||
| $428.21M-0.5% | $430.17M+0.3% | $429.08M+2.7% | $417.69M+7.9% | $387.24M+1.3% | ||
| -$106.3M+8.3% | -$115.88M+4.1% | -$120.87M-5.1% | -$115.05M-28.7% | -$89.36M+3.0% | ||
| -14.2%+1.7pp | -15.9%+1.1pp | -17%-0.4pp | -16.7%-3.4pp | -13.3%+0.7pp | ||
| $2.73M-27.2% | $3.75M-21.5% | $4.78M-17.9% | $5.82M-11.2% | $6.55M-1.0% | ||
| $6.62M-27.0% | $9.07M-23.6% | $11.88M-20.8% | $14.99M-13.5% | $17.31M-6.0% | ||
| $219K-26.0% | $296K+235% | -$219K-151% | $433K+949% | -$51K+86.5% | ||
| -$102.19M+7.3% | -$110.27M+3.3% | -$113.99M-8.1% | -$105.45M-34.1% | -$78.65M+2.5% | ||
| -$2.98M-32.9% | -$2.24M-330% | -$522K+63.0% | -$1.41M-32.8% | -$1.06M+45.5% | ||
| -$99.21M+8.2% | -$108.03M+4.8% | -$113.47M-9.1% | -$104.04M-34.1% | -$77.59M+1.4% | ||
| -13.3%+1.6pp | -14.9%+1.1pp | -16%-0.9pp | -15.1%-3.6pp | -11.5%+0.4pp | ||
| -$0.76+8.4% | -$0.83+5.7% | -$0.88-8.6% | -$0.81-32.8% | -$0.61+1.6% | ||
| 513.6M+0.3% | 511.8M+0.3% | 510.4M+0.3% | 508.9M+0.3% | 507.4M+0.2% | ||
| 513.6M+0.3% | 511.8M+0.3% | 510.4M+0.3% | 508.9M+0.3% | 507.4M+0.2% | ||
| -$0.76+8.4% | -$0.83+5.7% | -$0.88-8.6% | -$0.81-32.8% | -$0.61+1.6% | ||
| -$0.76+8.4% | -$0.83+5.7% | -$0.88-8.6% | -$0.81-32.8% | -$0.61+1.6% | ||
| —— | $27.75M+33.3% | $20.81M+50.0% | $13.88M+100% | $6.94M— | ||
| $219K-26.0% | $296K+235% | -$219K-151% | $433K+949% | -$51K+86.5% | ||
| -$106.3M+8.3% | -$115.88M+4.1% | -$120.87M-5.1% | -$115.05M-28.7% | -$89.36M+3.0% | ||
| -$39.79M+17.2% | -$48.06M+6.2% | -$51.25M-16.8% | -$43.89M-153% | -$17.36M+11.3% | ||
| -$39.79M+17.2% | -$48.06M+6.2% | -$51.25M-16.8% | -$43.89M-153% | -$17.36M+11.3% | ||
| -5.3%+1.3pp | -6.6%+0.6pp | -7.2%-0.9pp | -6.4%-3.8pp | -2.6%+0.4pp | ||
| -$106.3M+8.3% | -$115.88M+4.1% | -$120.87M-5.1% | -$115.05M-28.7% | -$89.36M+3.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is NeoGenomics's revenue?
- NeoGenomics (NEO) generated $746.0M in revenue over the trailing twelve months, up 10.9% year over year.
- Is NeoGenomics profitable?
- NeoGenomics is not currently profitable: it reported a net loss of $99.2M over the trailing twelve months, a -13.3% net margin.
- What are NeoGenomics's profit margins?
- Gross margin is 43.2% and operating margin is -14.2%, with a -13.3% net margin.
- What is NeoGenomics's earnings per share?
- NeoGenomics's diluted EPS over the trailing twelve months is $-0.76.
- Where does NeoGenomics's income statement data come from?
- Every line is extracted from NeoGenomics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
